Artiva Q2 net loss $25M; cash $349.4M; RMAT granted; Phase 3 RA trial to start H2 2026

Artiva Biotherapeutics, Inc.

Cash, cash equivalents and investments of $349.4M as of June 30, 2026, expected to fund operations into 2029.
Net loss of $25.0M for Q2 2026 vs $21.3M for Q2 2025; R&D expenses $21.9M vs $17.9M.
FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab for refractory RA.
Phase 3 randomized controlled trial of AlloNK plus rituximab vs rituximab alone in ~150 RA patients to start H2 2026.
Completed ~$300M underwritten offering in May 2026; appointed Diego Miralles, M.D., as president and head of R&D.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.